tradingkey.logo

Nexalin Technology Inc

NXL
0.515USD
-0.105-16.95%
Close 02/06, 16:00ETQuotes delayed by 15 min
9.37MMarket Cap
LossP/E TTM

Nexalin Technology Inc

0.515
-0.105-16.95%

More Details of Nexalin Technology Inc Company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc Info

Ticker SymbolNXL
Company nameNexalin Technology Inc
IPO dateSep 16, 2022
CEOWhite (Mark)
Number of employees6
Security typeOrdinary Share
Fiscal year-endSep 16
Address1776 Yorktown
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77056
Phone18322600222
Websitehttps://nexalin.com
Ticker SymbolNXL
IPO dateSep 16, 2022
CEOWhite (Mark)

Company Executives of Nexalin Technology Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
By RegionUSD
Name
Revenue
Proportion
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

Shareholding Stats

Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
Other
86.14%
Shareholders
Shareholders
Proportion
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
Other
86.14%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.78%
Investment Advisor
1.59%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
Other
82.35%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
38
722.74K
3.87%
-783.30K
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Elson (Marilyn)
1.54M
8.23%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.02%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.66%
--
--
Jun 04, 2025
Owens (David)
185.75K
1%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
176.58K
0.95%
+16.70K
+10.45%
Sep 30, 2025
MYDA Advisors LLC
150.00K
0.8%
-650.00K
-81.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
121.82K
0.65%
+5.45K
+4.69%
Sep 30, 2025
Kazden (Alan)
83.13K
0.45%
--
--
Jun 04, 2025
Susquehanna International Group, LLP
62.50K
0.34%
+62.50K
--
Sep 30, 2025
Renaissance Technologies LLC
55.70K
0.3%
+9.36K
+20.19%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI